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Background: Chronic depression represents a substantial portion of depressive disorders and is associated with
severe consequences. This review examined whether the combination of pharmacological treatments and
psychotherapy is associated with higher effectiveness than pharmacotherapy alone via meta-analysis; and identified
possible treatment effect modifiers via meta-regression-analysis.
Methods: A systematic search was conducted in the following databases: Cochrane Central Register of Controlled
Trials (CENTRAL), MEDLINE, EMBASE, ISI Web of Science, BIOSIS, PsycINFO, and CINAHL. Primary efficacy outcome
was a response to treatment; primary acceptance outcome was dropping out of the study. Only randomized
controlled trials were considered.
Results: We identified 8 studies with a total of 9 relevant comparisons. Our analysis revealed small, but statistically
not significant effects of combined therapies on outcomes directly related to depression (BR = 1.20) with substantial
heterogeneity between studies (I² = 67%). Three treatment effect modifiers were identified: target disorders, the type
of psychotherapy and the type of pharmacotherapy. Small but statistically significant effects of combined therapies
on quality of life (SMD= 0.18) were revealed. No differences in acceptance rates and the long-term effects between
combined treatments and pure pharmacological interventions were observed.
Conclusions: This systematic review could not provide clear evidence for the combination of pharmacotherapy
and psychotherapy. However, due to the small amount of primary studies further research is needed for a
conclusive decision.
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Approximately 20% of all patients who experience a major
depressive episode develop a chronic course [1] and approxi-
mately 47% of patients who are treated in mental health care
facility suffer from some form of chronic depression [2]. Four
subtypes of chronic depression are usually distinguished: (1)
dysthymia, (2) chronic major depression, (3) recurrent major
depression with incomplete remission between episodes, and
(4) double depression [3]. Dysthymic disorder is defined as a* Correspondence: a.von-wolff@uke.uni-hamburg.de
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reproduction in any medium, provided the ormild condition that is chronic and persistent for at least
2 years. Major depressive episode, chronic type, refers to a
more severe condition that meets full criteria for major de-
pression continuously for a minimum of 2 years. Patients
who have recovered to the point where they no longer meet
full criteria for a major depressive episode but continue to
experience significant symptoms for a total duration of illness
greater than 2 years are referred to as recurrent major de-
pression with incomplete remission during episodes. The
superimposition of a major depressive episode on antecedent
dysthymia is referred to as double depression [3].
Chronic depression is associated with increased func-
tional impairment [4], increased health care utilization,ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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chronic forms of depression [1,5].
An increasing number of studies have assessed the ef-
fectiveness of several pharmacological, psychotherapeutic,
and combined pharmacological and psychotherapeutic
interventions for the treatment of chronic depression in
the last several decades. Several meta-analyses have con-
firmed the effectiveness of pharmacological treatments
[6,7] and systematic reviews have highlighted the effective-
ness of psychotherapy in the treatment of chronically
depressed patients [8,9].
Because different effective interventions are available for
the treatment of chronic depression, a comparative ana-
lysis of the effectiveness of these different interventions is
of great clinical interest. Although, both systematic
reviews and current treatment guidelines recommend
combined psychotherapeutic and pharmacological inter-
ventions for the treatment of chronic depression, these
recommendations are based on a limited amount of evi-
dence [8-11].
Psychotherapy continues to face numerous barriers, such
as limited access in underserved areas and higher short-
term costs when delivered by mental health care profes-
sionals [12]. Therefore, the delineation of the conditions
under which combined treatment provides significantly
greater effectiveness than pure pharmacological interven-
tion is of high relevance. However, whether all patients re-
ceive equal benefit from the addition of psychotherapy to a
pharmacological intervention is not known. A recent meta-
analysis reported that the efficacy of psychotherapeutic
interventions increases with the number of sessions and
patients who suffer from dysthymia receive less benefit
from combined treatment compared to pharmacotherapy
alone than patients in other diagnostic subgroups [9].
Because new data on the comparative effectiveness of
combined interventions versus pharmacotherapy alone are
available from a large randomized controlled trial [13], we
decided to summarize empirical evidence on the effective-
ness of combined psychotherapeutic and pharmacological
treatments for chronic depression compared to pharmaco-
therapy alone by means of a systematic review. Our aim
was to especially focus on outcomes that are relevant for
clinicians who treat patients with chronic depression, such
as the response to treatment, remission, quality of life, and
acceptance of treatments (dropout), and to further exam-
ine whether the addition of psychotherapy to a pharmaco-
logical intervention is more effective in certain subgroups
of patients (e.g. according to diagnosis).
The objectives of this systematic review are to
examine whether the augmentation of pharmaco-
logical treatments with psychotherapy is associated
with higher effectiveness compared to pharmacother-
apy alone and identify possible treatment effect modi-
fiers, i.e. factors that may influence the size of effectsof augmentation of pharmacological treatments with
psychotherapy.
Methods
The methods and results are reported in accordance with
the Preferred Reporting Items for Systematic reviews and
Meta-Analysis (PRISMA) statement [14]. Methods were
specified a priori in a freely accessible review protocol that
included a detailed description of the methods, which are
summarized briefly here [15].
Eligibility criteria
Studies that were conducted in adults with a diagnosis
of chronic major depression, dysthymia, double depres-
sion, or recurrent depression without complete remis-
sion between episodes were included. The diagnosis of
depression had to rely on a formal classification system.
Studies focusing on preselected samples (e.g. predefined
comorbidities) of chronically depressed patients were
excluded.
Combined psychotherapeutic and pharmacological
interventions that focused primarily on the treatment of
depressive symptoms were considered. Only acute treat-
ments (no maintenance or continuation treatments)
were included. Psychotherapeutic interventions had to
fulfill the following criteria: 1) the intervention must be
based on a scientific theory; 2) a minimum of one con-
tact between therapist and patient must take place; and
3) the intervention must consider the personal needs of
the patient and must be individually tailored in an inter-
personal process. Combined interventions included the
administration of one or more antidepressant pharmaco-
logical agents combined with one or more psychothera-
peutic interventions. Somatic, non-pharmacological, and
organizational interventions were not considered.
The comparator treatment needed to be an anti-
depressant pharmacological intervention alone.
Only studies that reported at least one outcome to as-
sess the efficacy of the interventions and only rando-
mized controlled trials (RCTs) were included.
Search strategy
An electronic database search was conducted in the fol-
lowing databases on January 18, 2010: Cochrane Central
Register of Controlled Trials (CENTRAL), MEDLINE,
EMBASE, ISI Web of Science, BIOSIS, PsycINFO, and
CINAHL. A disease component was combined (AND)
with a design component for all searches: (((chron$ adj3
depress$) or dysthym$ or (double adj1 depress$) or
(treatment adj1 resist$ adj1 depress$) or (non adj1
respon$ adj3 depress$) or (recurrent adj3 depress$)).ab,ti,
sh.) AND ((random$ or rct).ab,ti. or random$.sh.) (e.g.,
MEDLINE). No language restrictions were applied and
all publications from 1970 forward were considered.
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Psychiatry, the Journal of Consulting and Clinical Psych-
ology, and the Journal of Affective Disorders were
searched by hand beginning with the year 1970. The
reference lists of all included studies and relevant
reviews were searched and a cited reference search in
the Social Sciences and Science Citation Index was per-
formed for all included studies. The first author of all
included studies was contacted for further information
regarding published and unpublished trials.
Study selection
Two reviewers independently screened title and abstract
of all identified articles. Next two reviewers independ-
ently examined the full texts of all potentially relevant
studies using inclusion criteria that were a priori
defined. Disagreement was resolved by discussion.
Data collection and assessment of methodological quality
A data extraction form of study characteristics, treat-
ment characteristics, sample characteristics and out-
comes was developed.
Risk of bias was assessed in accordance with the
Cochrane Collaboration’s Risk of Bias tool [16]. Two
researchers independently conducted the data extraction
of outcome data and the assessment of risk of bias. Dis-
agreements were resolved by discussion. The absolute
proportion of corresponding judgments and Cohen's
kappa coefficient were calculated to assess inter-rater
agreement.
Data synthesis
The primary efficacy outcome was the response to treat-
ment, which was defined as an at least 50% decrease on
a depression scale from baseline to the end of treatment.
Secondary efficacy outcomes included metric outcomes
of depression scales at the end of intervention and at
follow-up, the dichotomous outcome remission, and
metric outcomes on any quality of life scale. The pri-
mary acceptance outcome was dropping out of the study
due to any reason. The primary endpoint was the end of
intervention for all outcomes irrespective of intervention
duration. Follow-up was defined as at least 6 months
after the end of intervention.
The statistical analysis followed actual guidelines [16-18].
Effectiveness measures were benefit ratios (BR; a ‘risk ratio’
for positive endpoints) for dichotomous effectiveness out-
comes and odds ratios for dropout rates with correspond-
ing 95% confidence intervals (CI). Odds ratios were chosen
because we expected dropout rates to be a rare outcome
with highly varying baseline rates. Standardized mean dif-
ferences (SMD) were calculated for continuous measures.
Effect sizes were calculated using the intention-
to-treat principle for all studies. All randomized patientswere included in the analyses of primary outcomes irre-
spective of how the authors of the primary studies defined
their intention-to-treat sample. For secondary outcomes
the definition of the intention-to-treat sample provided by
the authors was followed. In all analyses a random effects
model with inverse variance weights were applied [19].
Statistical heterogeneity between study results was
tested for significance using Cochran’s Q-test and quan-
tified using the I² statistic [20].
Possible publication bias was investigated using visual
examination of funnel plots and applying Egger’s test
[21].
Meta-regression analysis
Heterogeneity among primary study findings was
explored using meta-regression analyses that exam-
ined a series of possible effect modifiers. A priori
defined analyses were performed according to the
type of psychotherapeutic intervention (brief support-
ive psychotherapy (BSP), cognitive behavioural ther-
apy (CBT), Cognitive Behavioural Analysis System of
Psychotherapy (CBASP), Interpersonal Psychotherapy
(IPT)), the subtype of chronic depression (percentage
patients with dysthymia, double depression, chronic
major depression, recurrent depression without
complete remission between episodes in the sample),
the onset and severity of the target disorder (percent-
age of patients who reported an early onset of the
disorder and baseline severity of depression), and
study quality (high quality vs. medium or low quality)
[15]. Additional a posteriori analyses were performed
according to the total number of patients included,
setting (outpatient vs. inpatient), the number of ses-
sions, treatment duration (in weeks), the use of se-
lective serotonin reuptake inhibitors (SSRIs) as
antidepressant medication, mean age of the sample,
and the percentage of females in the sample.
Inverse variance-weighted meta-regression models were
used to test possible effect modifiers formally [22-24].
Random effects models were estimated via the restricted
information maximum likelihood procedure. We chose to
conduct meta-regression analysis instead of subgroup ana-
lysis for categorical effect modifiers because this method
allows applying a random effects model and provides a
consistent framework for all analyses (metric as well as
categorical effect modifiers). All analyses were conducted
for two types of outcome measures: benefit ratios for
treatment response and standardized mean differences for
depressive symptoms at end of intervention. Bivariate as-
sociation of treatment effect modifiers were examined to
reveal possible multicollinearity.
In order to examine the influence of single studies on
the findings leave-one-out sensitivity analyses were con-
ducted for the primary outcomes response and dropout.
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formed for the meta-regression-analyses.
Analyses were performed using Review Manager 5 (The
Nordic Cochrane Centre, The Cochrane Collaboration,
Copenhagen) and PASW Statistics 18 (SPSS, Inc., Chicago,
IL) with an additional macro by Wilson [25].
Results
Study selection
After the removal of 1,710 duplicates 2,417 potentially
relevant publications were identified through the elec-
tronic database research (Figure 1). The number of pub-
lications was reduced to 304 through screening of title
and abstract. The hand searches identified another 49
possibly relevant studies. Of these 353 studies, seven
studies were not available. The full texts of the available
studies were screened and eight primary studies [13,26-
32] reported in 28 publications with a total of 1,618 par-
ticipants were included in the systematic review. The
included studies comprise a total of nine comparisons of
a combined intervention versus pharmacotherapy alone.
Study characteristics
The sample sizes ranged from N=26 to N=476. Most
studies (5/8) used SSRIs as the pharmacological interven-
tion. IPT was used as the psychotherapeutic intervention in
four studies, CBASP and CBT were each used in two stud-
ies and one study used BSP. Half of the studies (4/8) were
conducted in the United States. Most studies focused on
samples with a majority of dysthymic patients. The average
age of the study participants ranged from 37 to 45 years.
All studies included a majority of women. The detailed
characteristics of each study are presented in Table 1.Figure 1 Study flow diagram.Risk of bias within studies
The overall risk of bias was evaluated as “low” for five
studies and as “medium” for two studies. Only one study
was judged to have a “high” risk of bias. Knowledge of
allocation was adequately concealed in nearly all studies
(7/8), whereas an adequate concealment of the allocation
was reported in only four of the studies. The results of
the methodological quality assessment are presented for
individual studies in Table 2. Inter-rater agreement for
single quality assessment items ranged from 4/8 to 8/8
(kappa coefficients ranged from -.33 to 1.0).
Synthesis of results
One study reported two intervention arms with a com-
bined treatment and one arm with a pharmacological
treatment and thus provided two comparisons of interest
for the current meta-analysis [13]. We cut the number
of patients in the pharmacological arm in half for all
analyses to avoid including patients more than once in
the analysis.
The results of one study [30] proved to be an outlier
in the analysis of depressive symptoms at the end of
treatment; the effect size estimate differed strongly and
implausibly from the other studies (SMD approximately
ten times higher than any other estimate). This same
study was judged to have a high risk of bias. Therefore,
this study was excluded from all further analysis.
No statistically significant difference (at p< 0.05) in re-
sponse rates between combined treatments and pharma-
cological interventions alone were found. However,
combined treatments tended to be superior to pharmaco-
logical therapies (BR=1.20; 95% CI: 0.98-1.48; p = 0.08).
This result corresponds with a number needed to treat
Table 1 Study characteristics









Browne 2002[26] IPT Sertraline (SSRI) Dys, DD 42.2 68 12 24 476 Canada
deMello 2001[27] IPT Moclobemide Dys, DD 38.8 80 16 32 35 Brazil
Keller 2000[28] CBASP Nefazodone cMD, rec, DD 43.0 65 16 12 453 USA
Kocsis 2009[13] CBASP/BSP SSRIs cMD, rec, DD 45.4 55 16/18 12 491 USA
Markowitz 2005[29] IPT Sertraline (SSRI) Dys 42.3 63 16 16 45 USA
Miller 1999[30] CBT Amitriptyline/Desipramine Dys 37.4 81 40 20 26 USA
Ravindran 1999[31] CBT Sertraline (SSRI) Dys 38.0 58 12 12 47 Canada
Schramm 2008[32] IPT Sertraline (SSRI)/Amitriptyline cMD, DD 42.8 67 15 5 45 Germany
N se = number of psychotherapy sessions; N rand=patients randomized to relevant study arms; IPT = Interpersonal Psychotherapy; CBASP =Cognitive Behavioural
Analysis System of Psychotherapy; BSP = Brief Supportive Psychotherapy; CBT = Cognitive Behavioural Therapy; Dys = dysthymia; DD=double depression;
cMD= chronic major depression; rec = recurrent depression without complete remission between episodes.
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the greatest increase of the overall effect (BR= 1.29;
p = 0.01) after removal of the study by Browne and collea-
gues [26] and the greatest decrease (BR= 1.10; p = 0.25)
after removal of the study by Keller and colleagues [28].
A forest plot of this comparison is displayed in Figure 2.
Accordingly, the results for rates of remission (BR= 1.25;
95% CI: 0.97-1.61; p = 0.08; NNT=50) and depres-
sive symptoms at end of intervention (SMD=0.13; 95%
CI: -0.08-0.34; p = 0.22) indicated a possible superiority of
combined treatments compared to pharmacological treat-
ments alone. Again, none of these comparisons reached
statistical significance at p< 0.05.
Substantial statistical heterogeneity among the results
of the primary studies was observed for all outcomes
(I² = 67% for response; I² = 52% for remission; I² = 50%
for depressive symptoms).
Combined treatment showed statistically significantly
better quality of life outcomes than pure pharmacologicalTable 2 Risk of bias in individual studies
1 2 3 4 5 6 Global
Judgment
Browne 2002 yes yes yes yes yes no low
deMello 2001 unclear unclear yes unclear yes no medium
Keller 2000 yes yes yes yes yes yes low
Kocsis 2009 yes yes yes yes no yes low
Markowitz 2005 yes unclear yes yes yes yes low
Miller 1999 no yes unclear unclear no no high
Ravindran 1999 yes unclear yes yes no yes medium
Schramm 2008 yes unclear yes yes yes yes low
Summary “yes” 6/8 4/8 7/8 6/8 5/8 5/8 4/8
1: allocation sequence adequately generated; 2: allocation adequately
concealed; 3: knowledge of allocation adequately prevented; 4: incomplete
outcome adequately addressed; 5: free of selective outcome reporting; 6: free
of other problems.interventions at the end of active treatment (SMD=0.18;
95% CI: 0.07-0.29; p = 0.002).
Dropout rates did not differ statistically between com-
bined treatments and pharmacological interventions alone
(OR=0.84; 95% CI: 0.64-1.11; p = 0.21). These results were
not heterogeneous across studies (I² = 0%). Leave-one-out
sensitivity analysis showed the greatest increase of the
overall effect (OR=0.90; p = 0.56) after removal of the
study by Keller and colleagues [28] and the greatest de-
crease (OR=0.79; p = 0.15) after removal of the study by
Browne and colleagues [26].
Four studies provided data of depressive symptoms at
follow-up. Long-term effectiveness at an average of
12.5 months after end of active treatment was not statisti-
cally significantly different between combined and pharma-
cological treatments (SMD=0.25, 95% CI: -0.15-0.66;
p= 0.22).
Results for each individual study concerning each out-
come as well as overall effects are displayed in Table 3.Figure 2 Forest plot (response).
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With the exception of one study that was previously
judged as having a high risk of bias and implausibly large
effects [30], no indication of publication bias for the pri-
mary outcome response to treatment by visual examin-
ation of the funnel plot was observed (see Figure 3).
Accordingly, no indication for publication bias was
found when applying Egger’s test (beta = 0.01; p = 0.98).
Meta-regression analysis
As mentioned above substantial statistical heterogeneity
between studies was observed for the primary outcome
response to treatment and depressive symptoms at the
end of intervention. These findings indicate relevant
variation in effect sizes between studies. Therefore, fur-
ther exploration of this heterogeneity using meta-
regression analysis was conducted.
The results of the meta-regression analysis are presented
in Table 4. For both outcomes response to treatment as
well as depressive symptoms at end of interventions three
relevant treatment effect modifiers were identified. First,
combined treatment yielded significantly higher effects in
studies of patients with chronic major depression com-
pared to studies of patients who suffer from dysthymia
(p= 0.028). This result did not reach statistical significance
for the outcome depressive symptoms at end of interven-
tion (p= 0.252), but it accounted for nearly 70% of the ef-
fect variance across studies (as suggested by the R-squared
estimate). Expressed in differences of benefit ratios thisTable 3 Results of all outcomes (individual studies and overa
Response Remission Depres
BR (95% CI) BR (95% CI) short t
SMD (9
Browne 2002 0.97 (0.81,1.16) 0.94 (0.71,1.25) −0.07 (−
deMello 2001 1.37 (0.98,1.91) 1.45 (0.81,2.59) 0.48 (−0
Keller 2000 1.56 (1.33,1.84) 2.07 (1.46,2.95) 0.54 (0.
Kocsis (CBASP) 2009 1.07 (0.67,1.70) 1.11 (0.67,1.84) 0.12 (−0
Kocsis (BSP) 2009 0.85 (0.53,1.38) 0.91 (0.54,1.54) −0.06 (−
Markowitz 2005 0.98 (0.59,1.62) 1.26 (0.67,2.35) −0.27 (−
Miller 1999 11.27 (0.70,181.41) 1.29 (0.47,3.51) 4.15 (2.
Ravindran 1999 1.25 (0.78,1.99) 1.06 (0.57,1.95) 0.05 (−0
Schramm 2008 1.86 (1.02,3.40) 1.75 (0.80,3.84) 0.53 (−0
total
overall effect * 1.20 (0.98,1.48) 1.25 (0.97,1.61) 0.13 (−0
p for overall effect * 0.080 0.080 0.220
I² * 67% 52% 50%
p for heterogeneity * 0.004 0.040 0.050
1 = symptoms at end of intervention; 2 = symptoms at follow-up (follow-up ranged f
studies data are based on the Social Adjustment Scale; CI = confidence interval; SMD
CBASP = Cognitive Behavioural Analysis System of Psychotherapy; BSP = Brief Suppo
* results after removal of the study by Miller 1999.result indicates, that in a study with only dysthymic
patients the estimated benefit risk for response between a
combined treatment and a pure pharmacological treat-
ment would be 0.95, whereas in a study with patients suf-
fering from chronic major depression the estimated
benefit ratio would be 4.02. Leave-one-out sensitivity ana-
lysis revealed that the diagnostic subgroup did not serve
as a statistically significant treatment effect moderator
when the study by Keller and colleagues [28] or the study
by deMello and colleagues [27] were removed from the
analysis.
Apart from diagnostic subgroups the sample character-
istics of the studies such as mean age, percentage of
women, or percentage of patients reporting an early onset
of their disorder were not associated statistically signifi-
cantly with differences in effect sizes between combined
treatments and pure pharmacological interventions.
Second, in studies that added CBASP to a pharmaco-
logical intervention, differences between the combined
intervention and the pharmacological intervention were
significantly greater than in studies that used IPT
(p = 0.002 for response; p = 0.028 for severity of depres-
sion). IPT was used as reference intervention because it
was the most frequently used form of psychotherapy.
This effect corresponds to a benefit ratio of 1.07 for IPT
compared to an estimated benefit ratio of 1.49 for
CBASP. No effect of the number of psychotherapeutic
sessions or the duration of treatment was observed.
Leave-one-out sensitivity analysis revealed that the typell effect)
sive symptoms Quality of life3 Dropout
erm1 long term2 SMD (95% CI) OR (95% CI)
5% CI)
0.27,0.13) 0.04 (−0.16,0.24) 0.03 (−0.17,0.23) 0.98 (0.59,1.64)
.34,1.30) 0.50 (−0.38,1.38) 0.65 (−0.17,1.47) 0.44 (0.11,1.70)
19,0.89) not reported 0.29 (0.11,0.47) 0.76 (0.49,1.17)
.23,0.47) not reported 0.22 (−0.13,0.57) 0.71 (0.30,1.70)
0.41,0.29) not reported 0.07 (−0.28,0.42) 0.80 (0.34,1.90)
0.86,0.32) not reported 0.22 (−0.37,0.81) 0.89 (0.21,3.88)
78,5.52) 0.10 (−0.66,0.86) 1.15 (0.33,1.97) 1.36 (0.19,9.91)
.54,0.64) not reported 0.15 (−0.54,0.84) not estimable
.06,1.12) 0.63 (−0.06,1.32) not reported 3.17 (0.56,17.78)




rom 8 to 18 months after the end of intervention); 3 = in the case of three
= standardized mean difference; BR = benefit ratio; OR = odds ratio;
rtive Psychotherapy; p = level of significance; I² =measure of heterogeneity;
Legend:  
RR=Risk (benefit) Ratio; 
SE=Standard error 
Figure 3 Funnel plot.
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tistically significant treatment effect moderator when the
study by Keller and colleagues [28] or the study by
Browne and colleagues [26] were removed from the
analysis.
Third, in studies that used SSRIs as the pharmaco-
logical intervention, the add-on effect of the psycho-
therapeutic intervention was diminished compared to
studies that used other antidepressant medications
(p< 0.001 for response; p = 0.003 for severity of depres-
sion). This effect corresponds to an estimated benefit
ratio of 1.02 in a study that uses SSRIs s the antidepres-
sant medication (which indicates no differences in the
response rates between combined treatments and pure
pharmacological treatments) compared to an estimated
BR of 1.52 in study with other types of medication.
Leave-one-out sensitivity analysis revealed that the type
of medication did not serve as a statistically significant
treatment effect moderator when the study by Keller
and colleagues [28] was removed from the analysis.
The risk of bias of the individual studies and the num-
ber of patients that were included in the analysis did not
serve as treatment effect modifiers.
We conducted further exploratory multiple regression
analyses testing all three relevant effect modifiers (the
percent of patients with chronic major depression, the
use of CBASP as psychotherapeutic intervention and the
use of SSRIs as pharmacological intervention) in one
model. The results indicated that SSRIs significantly
reduced the effect of combined psychotherapeutic and
pharmacological interventions compared to a pure
pharmacological intervention (p = 0.021 for response;
p = 0.035 for severity of depression). However, the use of
CBASP as the psychotherapeutic intervention and the
percent of patients with chronic major depression didnot influence the differences in effect sizes between
combined interventions and pharmacological interven-
tions alone. Inter-correlations between the three treat-
ment effect modifiers were small to moderate and not
statistically significant (Spearman’s rho: -0.33 to 0.34).
Leave-one-out sensitivity analysis revealed that the type
of medication did not serve as a statistically significant
treatment effect moderator when the study by deMello
[27] was removed for the analysis for the outcome re-
sponse to treatment. No statistically significant effect was
found for the outcome depressive symptoms at end of
intervention after removal of the study by Keller and col-
leagues [28] or the study by Kocsis and colleagues [13].
Discussion
Summary
A small and statistically not significant effect of com-
bined psychotherapeutic and pharmacological interven-
tions on outcomes that are directly related to depression
(response, remission, symptom severity) with a substan-
tial variation of effect sizes between studies was revealed.
A more detailed meta-regression-analysis demonstrated
that this variation can be partly explained by differences
in target disorders (studies of patients suffering from
chronic major depression showed greater effects for
combined therapies than studies with dysthymic
patients), psychotherapy (CBASP yielded greater effects
for combined therapies than IPT), and pharmacotherapy
(SSRIs decreased the add-on effect of any psychother-
apy). Exploratory multiple regression analyses suggested
that the most important treatment effect modifier is the
use of SSRIs as the pharmacological intervention. The
finding of a small add-on effect of psychotherapy on de-
pressive symptoms in the treatment of chronic depres-
sion is consistent with previous findings [9], yet we
Table 4 Results of meta-regression analysis
Response (lnBR) Depression symptoms (SMD)
constant1 beta2 p R² constant1 beta2 p R²
% early onset 0.34 −0.30 .564 .06 0.43 −0.63 .255 .19
baseline severity −0.66 0.04 .160 .28 −0.89 0.05 .129 .32
diagnosis (reference
dysthymia)
−0.05 .69 −0.18 .69
% chronic MD 1.44 .028 0.88 .252
% recurrent without
remission
−1.16 .211 −0.88 .312
% double depression 0.40 .085 0.81 .111
mean age 1.46 −0.03 .463 .09 0.75 −0.02 .760 .01
% female −0.55 1.13 .373 .13 −0.77 1.43 .372 .12
sessions −0.13 0.02 .631 .03 −0.27 0.03 .560 .04
treatment duration
(weeks)
0.31 −0.01 .521 .06 0.37 −0.02 .137 .19
setting outpatient (vs.
inpatient)
0.39 −0.24 .348 .15 0.29 −0.20 .469 .07
type of PT (reference
IPT)
0.07 .57 −0.01 .40
CBT 0.15 .555 0.06 .846
CBASP 0.33 .002 0.34 .028
BSP −0.23 .365 −0.05 .807
type of medication
SSRI (vs. others)
0.42 −0.40 ≤.001 .72 0.53 −0.54 .003 .64
low risk of bias (vs.
medium)
0.28 −0.12 .599 .05 0.21 −0.10 .754 .01
total N in study 0.23 −0.00 .756 .02 0.13 0.00 .980 .00
multiple regression
analysis
0.33 0.79 0.38 .78
% chronic MD 0.51 .317 0.54 .237
CBASP −0.66 .769 −0.01 .969
type of medication
SSRI (vs. others)
−0.35 .021 −0.46 .035
1 unstandardized regression constant (equals treatment effect reference category) 2 unstandardized regression weight; positive values indicate superiority of the
add-on psychotherapy to medication over medication alone; lnBR = natural logarithm of Benefit Risk; SMD= Standardized Mean Difference; p = level of
significance; R² = explained variance; MD=Major Depression; PT = psychotherapy; IPT = Interpersonal Psychotherapy; CBT = Cognitive Behavioural Therapy;
CBASP = Cognitive Behavioural Analysis System of Psychotherapy; BSP = Brief Supportive Psychotherapy.
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The lack of statistical significance in this study might be
partly due to the smaller amount of studies included in
this meta-analysis (which was due to stricter inclusion cri-
teria concerning methodological aspects of the primary
studies) and exclusion of an extraordinary positive outliner
study. Because the diagnostic subgroup and the type of
antidepressant medication was not confounded in our ana-
lysis (as it was in the preceding meta-analysis [9]), the as-
sumption that the most relevant effect modifier when
comparing combined treatments to pure pharmacological
treatments is the type of the antidepressant medication,
primarily the use of SSRIs, was strengthened. Even though
previous findings showed that studies reporting a lagernumber of treatment session resulted in lager effect sizes
for pure psychotherapeutic interventions [9], no correlation
between the number of psychotherapeutic sessions and the
superiority of combined treatments could be shown.
Small but statistically significant add-on effects of psy-
chotherapy on the quality of life of chronically depressed
patients were demonstrated. No differences in accept-
ance rates (dropout rates) or long-term effects between
combined treatments and pure pharmacological inter-
ventions were observed.
Limitations
Several limitations of the current literature emerged upon
this review. First, the sample sizes of primary studies
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http://www.biomedcentral.com/1471-244X/12/61varied greatly and the overall number of studies that were
suitable for the systematic review was rather small. There-
fore, our analyses were primarily dominated by three
large-scale studies [13,26,28]. Leave-one-out sensitivity
analyses revealed that single studies had only rather small
effects on the results of the meta-analyses, yet the results
of the meta-regression-analysis are largely dominated by
one study [28] that reported unequivocally positive results
for the use of CBASP as add-on psychotherapy to anti-
depressant medication with nefazodone. Beside the ana-
lyses of a number of a priori defined treatment effect
modifiers we conducted additional explorative meta-
regression analyses whose interpretation needs to be con-
sidered preliminary. Altogether the number of examined
effect moderators was large, particularly in relation to the
small number of studies. Therefore we advise careful inter-
pretation of these findings as causal evidence and consider
them as observational hypotheses that need further
investigation.
Another shortcoming of our review is that the pre-
sented evidence is based on clinical trials which focus on
high internal validity, yet implementation of combined
treatments in routine care is connected to certain chal-
lenges. For example patients may perceive practical and
emotional barriers prior to psychotherapeutic treatment
[33] and the careful management of side effects and
interaction effects of complex medication regimes might
be more difficult in routine care. To manage both treat-
ments adequately collaborative care models need to be
considered as recent research has shown their effective-
ness for other forms of depression [34]. Thus, evidence
from routine care is needed to conclusively evaluate the
add-on effect of psychotherapy.
Third, results of the long-term add-on effect of psy-
chotherapy are preliminary, as only four studies provided
relevant data. More research is required because of the
high risk of relapse in chronic depression.
Conclusions
This systematic review could not provide clear evidence for
the augmentation of pharmacotherapy with psychotherapy
in the treatment of chronic depression. Our findings indi-
cate that the role of add-on psychotherapy may be of more
limited value than suggested in current literature [9] and
clinical practice guidelines on treatment of chronic depres-
sion [10,11]. However, psychotherapy may be a relevant fac-
tor for the treatment of chronic depression due to several
reasons. First, augmentation of pharmacotherapy with psy-
chotherapy can lead to significant gains in outcomes that
are highly relevant for patients, such as quality of life. Sec-
ond, patients often prefer psychotherapy over medication
[35]. Third, as patients’ preference can influence treatment
adherence patient’s choice should be considered in the
planning of an optimal treatment strategy.The heterogeneity across studies further highlighted
the relevance of the optimization of both psycho-
therapeutic and pharmacological interventions to in-
crease treatment effects. Our analysis revealed a high
impact of SSRIs on the comparative effectiveness of
treatment strategies. One explanation for this finding
could be that the non-SSRI antidepressants (e.g.,
moclobemide, nefazodone) are in combination with
psychotherapeutic interventions less effective than
SSRIs in combination with psychotherapeutic inter-
ventions, yet further evidence on the direct compari-
son of the different types of antidepressants is needed
to conclusively interpret this finding. Therefore, in
further studies of the combination of pharmacother-
apy with psychotherapy SSRIs should be used as a
comparator. The heterogeneity across studies further
indicated that the category chronic depression sub-
sumes clinically heterogeneous subgroups. Especially
patients suffering from dysthymia and chronic major
depression seem to respond differently to certain
treatment strategies.
Further research on the cost-effectiveness, long-term
outcomes and the role of psychotherapy in the continu-
ation and maintenance treatment of chronically depressed
patients is required to conclusively assess the value of psy-
chotherapy as an add-on treatment to pharmacotherapy.
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